Business Context and Reporting Period
This Form 8-K is a current report filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on September 19, 2024, covering events occurring on September 15, 2024. The company is a Delaware corporation with its principal executive offices in Pacific Palisades, California, and its common stock trades on The Nasdaq Stock Market under the symbol "AADI."
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on executive compensation arrangements.
Material Changes
The primary material event reported is the approval and execution of a retention bonus program for key executive officers:
- David J. Lennon, Ph.D. (President and CEO): Approved a retention bonus of $390,000.
- Scott Giacobello (CFO): Approved a retention bonus of $220,000.
These bonuses are contingent on the executives remaining employed through the earlier of March 31, 2025, or a Change of Control. The bonuses are payable within ten business days following the retention date.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, market outlook, or general risk factors. However, it outlines specific contingencies regarding the retention bonuses:
- If the Company terminates an executive other than for Cause, or if an executive resigns for Good Reason prior to the Retention Date, the executive is entitled to a lump-sum severance payment equal to the full retention bonus amount.
- Receipt of severance is subject to the execution of a separation agreement and release of claims.
Investor Verification Checklist
- Verify the exact terms of the "Retention Bonus Letter" (Exhibit 10.1) regarding definitions of "Cause," "Disability," and "Good Reason."
- Confirm the total potential cash outflow of $610,000 for the two executives if the retention period is completed or if severance is triggered.
- Review the company's cash position in recent 10-Q or 10-K filings to assess the impact of these potential payouts on liquidity.
- Note the discrepancy between the requested company name (Whitehawk Therapeutics) and the actual registrant (Aadi Bioscience).